Charité - Universitätsmedizin Berlin

PRECYCLE Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy (2019) Degenhardt T, Fasching P, Lueftner D, Mueller V, Thomssen C, Schem C, Witzel I, et al. Conference contribution Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials (2019) Werutsky G, Untch M, Hanusch C, Fasching P, Blohmer JU, Seiler S, Denkert C, et al. Conference contribution Utility of the CPS plus EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy (2019) Marme F, Solbach C, Michel L, Fasching P, Schneeweiss A, Blohmer JU, Rezai M, et al. Conference contribution A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours (2019) Krauss J, Eigentler T, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, et al. Conference contribution Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen (2019) Ruszniewski P, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, et al. Conference contribution Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition) (2019) Cossarizza A, Acs A, Adam D, Adam-Klages S, Agace WW, Aghaeepour N, Akdis M, et al. Journal article S3 guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 1 (2019) Mahler V, Nast A, Bauer A, Becker D, Brasch J, Breuer K, Dickel H, et al. Journal article S3-Leitlinie: Durchführung des Epikutantests mit Kontaktallergenen und Arzneimitteln – Kurzfassung Teil 1 (2019) Mahler V, Nast A, Bauer A, Becker D, Brasch J, Breuer K, Dickel H, et al. Journal article Delineating the clinical spectrum due to heterozygous TRAF7 missense mutations: A series of 38 cases (2019) Amiel J, Mishra K, Castilla L, Selmer KK, Barak T, Yang S, Blanco-Sanchez B, et al. Conference contribution CLINICAL AND VIROLOGICAL CHARACTERISTICS AND RETREATMENT OF HCV-INFECTED PATIENTS WITH FAILURE TO MULTIPLE SUBSEQUENT DAA THERAPIES (2019) Dietz J, Vermehren J, Peiffer KH, Wietzke-Braun P, Muellhaupt B, Schattenberg J, Antoni C, et al. Conference contribution